{"id":295554,"date":"2023-11-03T00:00:00","date_gmt":"2023-11-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0038-2023-biopharma-attention-deficit-hyperactivity-disorder-access-reimbursement-access-and\/"},"modified":"2026-03-31T10:31:52","modified_gmt":"2026-03-31T10:31:52","slug":"acrecg0038-2023-biopharma-attention-deficit-hyperactivity-disorder-access-reimbursement-access-and-reimbursement","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0038-2023-biopharma-attention-deficit-hyperactivity-disorder-access-reimbursement-access-and-reimbursement\/","title":{"rendered":"Attention-Deficit-Hyperactivity Disorder &#8211; Access &#038; Reimbursement &#8211; Access and Reimbursement &#8211; Attention-Deficit\/Hyperactivity Disorder (US)"},"content":{"rendered":"<p>Attention-deficit \/ hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at any age. Treatment options include a mix of stimulants (e.g., methylphenidates, amphetamines) and nonstimulants (e.g., dopaminergic\/noradrenergic agents, adrenergic receptor agonists), many of which are available generically. Despite many available\u2014and largely efficacious\u2014pharmacological treatments, a large proportion of patients have inadequate control of their ADHD symptoms, including over the long term. Thus, novel agents continue to launch in this large and genetic market, seeking to provide better or longer control of symptoms and are largely used in later lines of therapy. The expanding presence of generic drugs has given payers more leverage to control drug treatment costs in ADHD. Given this challenging market for novel brands, understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice is key for developers of new therapies for ADHD.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>In this mature and highly generic treatment landscape, what actions can marketers of therapies for ADHD take to gain market access and ensure uptake?<\/li>\n<li>How do payer policies affect the prescribing of branded psychostimulants (e.g., Supernus\u2019s Qelbree, Corium\u2019s Azstarys, Aytu Biopharma\u2019s CotemplaXR-ODT) in this genericized market?<\/li>\n<li>To which of their ADHD patients do physicians anticipate prescribing Otsuka Pharmaceuticals\u2019 centanafadine, Arbor Pharmaceuticals\u2019 amphetamine sulfate-ODT, and Noven\u2019s dexamfetamine transdermal patch? How do payers expect to reimburse these therapies?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS <\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. <abbr data-abbreviation-entity=\"4927\" title=\"primary care physician\">PCP<\/abbr>s, psychiatrists, pediatricians, and pediatric psychiatrists, survey of 30 U.S. <abbr title=\"managed care organization\">MCO <\/abbr><abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s<\/p>\n<p><strong>Fingertip formulary: <\/strong>Formulary coverage and restrictions data for ADHD therapies by commercial plans covering approximately 169.5 million lives nationally.<\/p>\n<p><strong>Key marketed drugs covered: <\/strong>Adzenys XR-ODT, Dyanavel XR, Evekeo ODT, Mydayis, Vyvanse, Azstarys, Cotempla XR-ODT, Jornay PM, Quillichew ER, Qelbree, Xelstrym<\/p>\n<p><strong>Emerging therapies:<\/strong> Centanafadine (Otsuka), CTx-1301 (Cingulate), solriamfetol (Axsome)<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Reimbursement and contracting.<\/p>\n<p>Access and prescribing.<\/p>\n<p>Opportunities and challenges for emerging therapies.<\/p>\n<p>Disease-specific special topics:<\/p>\n<ul>\n<li>Impact of the mixed amphetamine salts IR shortage on access and reimbursement in ADHD<\/li>\n<li>Assessing physician and payer attitudes toward digital therapeutics (DTx) for ADHD<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-295554","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-attention-deficit-hyperactivity-disorder","biopharma-therapy-areas-psychiatry","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295554\/revisions"}],"predecessor-version":[{"id":576053,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295554\/revisions\/576053"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}